← Back to Search

Other

Cocktail Probe Substrates + BMS-986419 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 28 days after last dose
Awards & highlights

Study Summary

This trial tests the effects of a drug on 6 common medicines in healthy people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 28 days after last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days after last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))
Columbia-Suicide Severity Rating Scale (C-SSRS)
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cocktail Probe Substrates + BMS-986419Experimental Treatment7 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fexofenadine
2016
Completed Phase 4
~950
BMS-986419
2023
Completed Phase 1
~30
Caffeine
2014
Completed Phase 3
~2980
Bupropion
2011
Completed Phase 4
~3310
Omeprazole
2006
Completed Phase 4
~940
Flurbiprofen
2022
Completed Phase 4
~870
Midazolam
2018
Completed Phase 4
~1910

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,130,810 Total Patients Enrolled

Media Library

BMS-986419 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05932277 — Phase 1
Healthy Subjects Research Study Groups: Cocktail Probe Substrates + BMS-986419
Healthy Subjects Clinical Trial 2023: BMS-986419 Highlights & Side Effects. Trial Name: NCT05932277 — Phase 1
BMS-986419 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05932277 — Phase 1
~12 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top